"The U.S. Food and Drug Administration today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with ge"...
Hematopoietic toxicity can occur following overdose, manifested by a decrease in the white cell count and/or platelets. Red blood cell count is a less accurate indicator of thiotepa (thiotepa (thiotepa injection) injection) toxicity. Bleeding manifestations may develop. The patient may become more vulnerable to infection, and less able to combat such infection.
Dosages within and minimally above the recommended therapeutic doses have been associated with potentially life-threatening hematopoi-etic toxicity. Thiotepa (thiotepa (thiotepa injection) injection) has a toxic effect on the hematopoietic system that is dose related.
Thiotepa (thiotepa (thiotepa injection) injection) is dialyzable.
There is no known antidote for overdosage with thiotepa (thiotepa (thiotepa injection) injection) . Transfusions of whole blood or platelets have proven beneficial to the patient in combating hematopoietic toxicity.
Thiotepa (thiotepa (thiotepa injection) injection) is contraindicated in patients with a known hypersensitivity (allergy) to this preparation.
Therapy is probably contraindicated in cases of existing hepatic, renal, or bone-marrow damage. However, if the need outweighs the risk in such patients, thiotepa (thiotepa (thiotepa injection) injection) may be used in low dosage, and accompanied by hepatic, renal and hemopoietic function tests.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 11/20/2008
Additional Thiotepa Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.